Evaluation of neuroendocrine markers in renal cell carcinoma.
BACKGROUND
The purpose of the study was to examine serotonin, CD56, neurone-specific enolase (NSE), chromogranin A and synaptophysin by immunohistochemistry in renal cell carcinomas (RCCs) with special emphasis on patient outcome.


METHODS
We studied 152 patients with primary RCCs who underwent surgery for the removal of kidney tumours between 1990 and 1999. The mean follow-up was 90 months. The expression of neuroendocrine (NE) markers was determined by immunohistochemical staining using commercially available monoclonal antibodies. Results were correlated with patient age, clinical stage, Fuhrman grade and patient outcome.


RESULTS
Eight percent of tumours were positive for serotonin, 18% for CD56 and 48% for NSE. Chromogranin A immunostaining was negative and only 1% of the tumours were synaptophysin immunopositive. The NSE immunopositivity was more common in clear cell RCCs than in other subtypes (p = 0.01). The other NE markers did not show any association with the histological subtype. Tumours with an immunopositivity for serotonin had a longer RCC-specific survival and tumours with an immunopositivity for CD56 and NSE had a shorter RCC-specific survival but the difference was not significant. There was no relationship between stage or Fuhrman grade and immunoreactivity for serotonin, CD56 and NSE.


CONCLUSIONS
Serotonin, CD56 and NSE but not synaptophysin and chromogranin A are expressed in RCCs. However, the prognostic potential of these markers remains obscure.
Ronkainen
Hanna
H
Department of Surgery, PO Box 21, Oulu University Hospital, FIN-90029 Oulu, Finland. hanna.ronkainen@mail.suomi.net
Soini
Ylermi
Y
Vaarala
Markku H
MH
Kauppila
Saila
S
Hirvikoski
Pasi
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D019002:CD56 Antigen / Q000032:analysis; D002292:Carcinoma, Renal Cell / Q000737:chemistry* / Q000401:mortality / Q000601:surgery; D016009:Chi-Square Distribution; D053379:Chromogranin A / Q000032:analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010751:Phosphopyruvate Hydratase / Q000032:analysis; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012701:Serotonin / Q000032:analysis; D015996:Survival Rate; D016708:Synaptophysin / Q000032:analysis; D013997:Time Factors; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D019002:CD56 Antigen; D053379:Chromogranin A; C522918:NCAM1 protein, human; D016708:Synaptophysin; D012701:Serotonin; D010751:Phosphopyruvate Hydratase
Am J Transl Res. 2009 Feb 05;1(2):148-62
19956427
Science. 1989 Jun 2;244(4908):1057-62
2727693
Oncol Rep. 2005 Dec;14(6):1593-7
16273262
Ann Med. 2000 Apr;32(3):187-94
10821326
Nature. 1967 Jul 1;215(5096):58-9
6053402
Hum Pathol. 2003 Jun;34(6):528-32
12827605
Anticancer Res. 1996 Nov-Dec;16(6B):3871-4
9042273
Acta Oncol. 1999;38(5):623-8
10427952
N Engl J Med. 2003 Mar 20;348(12):1134-49
12646671
Adv Anat Pathol. 2004 Jul;11(4):175-89
15220821
Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;58(2):95-121
2575822
Int J Gynecol Pathol. 2009 Mar;28(2):142-7
19188820
Crit Rev Oncol Hematol. 1991;11(2):109-35
1657028
Prostate. 2004 May 15;59(3):328-36
15042609
Am J Pathol. 1987 Feb;126(2):243-57
3103452
Int Urol Nephrol. 1996;28(2):207-10
8836790
Pathol Res Pract. 1988 Apr;183(2):214-21
3290869
J Urol. 2002 Sep;168(3):1204-11
12187268
Oncol Rep. 2009 Mar;21(3):757-60
19212636
World J Urol. 2008 Oct;26(5):499-504
18581119